Figure 2.
Preclinical and early clinical strategies to optimize CAR T-cell therapy in B-NHL. (A) Modification of CAR T-cell design. (B) Identification of novel tumor antigen targets. ROR1, receptor tyrosine kinase-like orphan receptor 1; scFv, single-chain variable fragment.

Preclinical and early clinical strategies to optimize CAR T-cell therapy in B-NHL. (A) Modification of CAR T-cell design. (B) Identification of novel tumor antigen targets. ROR1, receptor tyrosine kinase-like orphan receptor 1; scFv, single-chain variable fragment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal